Procedures
thrombosis, bleeding, SARS-CoV-2 infection, abnormal fasting blood glucose or diabetes, coagulation abnormalities
THROMBOSIS, BLEEDING, SARS-COV-2 INFECTION, ADVERSE EVENTS, ADVERSE EVENT, CHRONIC DISEASES, DISEASES
Participants aged 18 years or older were selected by an oral consultant according to inclusion and exclusion criteria. Criteria for critical exclusion included participants with 1) a history of SARS-CoV-2 infection or vaccination, 2) severe chronic diseases, 3) abnormal fasting blood glucose or diabetes, or 4) diagnosed coagulation abnormalities or diseases prone to thrombosis or bleeding. Other detailed inclusion and exclusion criteria are listed on ClinicalTrials.gov (NCT04953325).A total of 270 participants were recruited and randomly assigned to the CoronaVac group and the control group in a 2:1 ratio. There were 180 participants in the CoronaVac group (including 90 adults aged 18–59 years and 90 adults aged 60 years or older) who received two doses of CoronaVac in a 28-day interval and 90 participants (including 45 adults aged 18–59 years and 45 adults aged 60 years or older) in the control group who received one dose of PPV23 on day 0 and one dose of inactivated HepA vaccine on day 28.For safety assessment, participants were required to record the solicited adverse events on paper for the first 7 days after each dose and the unsolicited adverse events for 28 days after each dose. Serious adverse events were recorded throughout the trial. Adverse events were classified according to the guidelines released by the China NMPA (